The US FDA recently rolled out its generative artificial intelligence tool, Elsa.
“Elsa is a large language model–powered AI tool designed to assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications. These are just a few examples of how Elsa will be used across the enterprise to improve operational efficiency,” says FDA.gov.
As also noted by Precedence Research:
With the ability to process and analyze massive amounts of data, AI is revolutionizing patient care, clinical trials, drug discovery, and administrative tasks. From diagnostic tools to personalized treatments, AI technology is helping healthcare professionals make more informed decisions faster.
In addition, by using artificial intelligence, the company can help accelerate drug discovery, shorten the development process, reduce costs and identify more effective treatments.
That should have a positive impact on stocks like Recursion Pharmaceuticals (SYM: RXRX).
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery.
Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
By using artificial intelligence, the company can help accelerate drug discovery, shorten the development process, reduce costs and identify more effective treatments.
In short, AI and Recursion have the potential to make the long, arduous drug discovery process quicker and less expensive.
There’s also Schrodinger (SYM: SDGR).
At the moment, SDGR is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design.
The company’s software allows researchers to design, model, and predict the properties of molecules in silico, or by using computer software. Some of its key products include Maestro (modeling environment), LiveDesign (molecular design), FEP+ (predicts binding affinity of ligands to protein targets), and Glide (high-throughput virtual screening) to name a few.
Trending Now: America's Finest Hour?
